Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection

Farzan Solimani, Katharina Meier and Kamran Ghoreschi

Department of Dermatology, Venereology and Allergology, Charité–Universitätsmedizin Berlin, Berlin, Germany

Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During initial SARS-CoV-2 infection, symptomatic patients present with impaired type I/III IFN-mediated antiviral responses. Interestingly, IFNs regulate the cellular entry receptor for SARS-CoV-2 on epithelial and endothelial cells. As reported recently, critically ill COVID-19 patients show genetic polymorphisms in one IFN receptor gene (IFNRA2) and in a gene locus near the Janus kinase (JAK) TYK2, which is key for IFN, interleukin (IL)-12 and IL-23 signaling, and T helper (Th) 1/Th17 cell-mediated antiviral immune responses. In the advanced stage of the disease, critically ill COVID-19 patients develop a cytokine storm where many inflammatory mediators using the JAK/STAT signaling pathway such as IL-6, IFN-γ, the granulocyte colony-stimulating factor (G-CSF) or IL-2, and chemokines result in an influx of macrophages and neutrophils damaging the lung tissue. The knowledge on the cytokine and JAK/STAT signaling pathways in severe COVID-19 disease explains the promising first results with JAK inhibitors like baricitinib, which not only dampen the inflammation but in the case of baricitinib also affect virus replication and endocytosis in target cells. Here, we summarize the current immunological associations of SARS-CoV-2 infection with cytokine signaling, the JAK/STAT pathway, and the current clinical stage of JAK inhibitors for improving severe COVID-19 disease.

Keywords: Janus kinase • JAK inhibitors • SARS-CoV-2 • severe COVID-19 • cytokine storm

Introduction

Twelve months after the outbreak of the COVID-19 pandemic in the Hubei province of China [1], the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still stressing societies and healthcare systems around the world. In the end of 2020, the first vaccines against the novel coronavirus have been approved by the U.S. and European authorities [2, 3]. Albeit many regions of the world are currently experiencing an increase in infections and deaths, the impact of the vaccines on this pandemic will be tangible earliest in several months. We are still in a threatening situation where we need to improve our understanding on COVID-19 disease and therapeutic management to refine the current standard of care. So far, several different therapeutic approaches including antiviral drugs, anti-inflammatory agents, immunotherapies, or a combination of such therapies have been tested [4]. One important support for clinicians emerges from immunological studies aiming to characterize the inflammatory response in infected patients. While the majority of patients display mild to moderate respiratory problems, a subgroup—especially elderly individuals and/or those with certain comorbidities—develop severe respiratory distress and systemic inflammation, where an impaired virus specific T-cell answer and the production of inflammatory cytokines eventually results in a cytokine storm syndrome [5–7]. This phenomenon is not based on viral load but rather on the individual immune answer to the virus. At this stage, patients...
importance of cytokine signaling through Janus kinases (JAK) during SARS-CoV-2 lung infection. Viral endocytosis in lung epithelial cells begins through the ACE2 receptor, which is regulated by IFN signaling. The initial antiviral response mediated by type I/III IFNs and downstream JAK/STAT signaling is impaired in severely ill patients. In these patients with progressive disease, SARS-CoV-2 infection triggers an excessive immune reaction with release of multiple pro-inflammatory cytokines such as IL-2, IL-6, granulocyte colony stimulating factor (G-CSF) that signal through the JAK/STAT pathway, and others like TNF. Infiltrating macrophages and neutrophils contribute to lung injury. A genetic susceptibility with polymorphisms in or near the genes for IFNAR2 and TKY2, respectively, and the development of autoantibodies against IFNs favor the inflammatory profile in severely ill patients. The JAK1/JAK2 inhibitor baricitinib exerts antiviral effects by hampering virus endocytosis and profound anti-inflammatory effects in severely ill patients by blocking cytokine signaling.

Figure 1. Importance of cytokine signaling through Janus kinases (JAK) during SARS-CoV-2 lung infection. Viral endocytosis in lung epithelial cells begins through the ACE2 receptor, which is regulated by IFN signaling. The initial antiviral response mediated by type I/III IFNs and downstream JAK/STAT signaling is impaired in severely ill patients. In these patients with progressive disease, SARS-CoV-2 infection triggers an excessive immune reaction with release of multiple pro-inflammatory cytokines such as IL-2, IL-6, granulocyte colony stimulating factor (G-CSF) that signal through the JAK/STAT pathway, and others like TNF. Infiltrating macrophages and neutrophils contribute to lung injury. A genetic susceptibility with polymorphisms in or near the genes for IFNAR2 and TKY2, respectively, and, the development of autoantibodies against IFNs favor the inflammatory profile in severely ill patients. The JAK1/JAK2 inhibitor baricitinib exerts antiviral effects by hampering virus endocytosis and profound anti-inflammatory effects in severely ill patients by blocking cytokine signaling.

Targeting single cytokines as immunotherapy for COVID-19

Due to the knowledge on the cytokine pattern in patients infected with SARS-CoV-2, the current drug interventions for hospitalized patients requiring supplemental oxygen or ventilation comprise a combination of antiviral agents like remdesivir together with anti-inflammatory drugs like dexamethasone. The prominent production of IL-6 as induced by SARS-Cov-2 led to the use of monoclonal antibodies directed against the IL-6 receptor in hospitalized patients very early on. In the meanwhile, first phase 3 trials with tocilizumab and sarilumab (both blockers of the IL-6 receptor) in the setting of severe COVID-19 pulmonary disease have been published with contradictory results. However, some patients may benefit from IL-6 blockade [10–12]. Yet, immunotherapies targeting a broader range of cytokines or their signaling events may offer better strategies. Remarkably, patients with the chronic IL-17/IL-23-dominated inflammatory skin disorder psoriasis receiving immune treatments (i.e., anti-IL-17/anti-IL-23 monoclonal antibodies or phosphodiesterase 4 inhibitor) seemingly show a lower risk for adverse outcomes during SARS-CoV-2 infection [13, 14].
importance of type I/III IFN responses during SARs-CoV-2 infection

Severely affected COVID-19 patients seem to present with an insufficient induction of type I and type III IFNs during initial illness [15, 16]. This is in contrast to the situation seen in patients with influenza infections, where a sufficient IFN-dominated antiviral response typically appears upon contact of the host's pattern recognition receptors to viral RNA [5, 8]. Of note, a subgroup of patients with life-threatening COVID-19 pneumonia shows neutralizing autoantibodies against IFNs at the onset of critical disease [17] (Fig. 1). On the other hand, type I IFNs limit excessive virus-dependent inflammatory lung injury by inducing IL-10, as observed in experimental influenza infection [18]. Finally, type I IFNs critically regulate the expression of the cellular entry receptor for SARS-CoV-2 (ACE2) in airway epithelial cells, enterocytes of the small intestine, and endothelial cells [19, 20]. Presumably, this regulation is more critical during the initial infection phase of the disease. Thus, type I/III IFN receptor subunits (IFNAR1/IFNAR2 or IFNλR1/IL10R2) and their associated signaling proteins of the Janus kinase (JAK) family (JAK1 and TYK2) are of special relevance in COVID-19 patients. Genetic findings further underline the relevance of cytokine receptor signaling pathways in viral infections and COVID-19 disease. Single cases of human IFNAR1/IFNAR2 deficiencies report from fundamental complications after vaccination with live attenuated viruses [21, 22]. Likewise, TYK2-deficient patients show impaired cellular responses to IL-12, IL-23, and type I IFNs and present higher susceptibility for viral infections [23]. Importantly, a genome-wide association study conducted in 2244 critically ill COVID-19 patients unraveled significant associations on chr21q22.1 (rs2236757) in the gene locus of IFNAR2 and on chr19p13.3 (rs74956615) near the gene encoding TYK2 [24]. Here, Pairo-Castineira et al. further analyzed these findings by Mendelian randomization, finding an association between IFNAR2 low expression, TYK2 high expression, and severe disease course [24].

JAK inhibitors for treatment of severe COVID-19

Based on this pivotal role for type I and III IFNs, therapeutic approaches with IFN-α or IFN-β have been tried, though they were of limited benefit in COVID-19 patients, indicating that the early antiviral and anti-inflammatory effects of type I IFN cytokine administration are not sufficiently protective. As suggested very early during the pandemic, a broader inhibition of the cytokine storm may be of greater relevance [25, 26]. Inhibitors that inhibit JAKs exert potent anti-cytokine effects and dampen the signals of multiple factors that are increased in SARS-CoV-2-infected individuals (e.g., IL-2, IL-6, IL-7, IFN-α, IFN-γ, and G-CSF). Such inhibitors should target at least JAK1, preferentially in combination with JAK2 or even TYK2. Initial positive results with the JAK1/JAK2 inhibitor ruxolitinib were reported from an Italian study. A small cohort of COVID-19 patients with severe pulmonary disease (n = 34) was treated with ruxolitinib. As published, amelioration of pulmonary function was observed in about 85% of the patients [27]. Another JAK inhibitory compound that has been extensively tested in the setting of SARS-CoV-2 is baricitinib, a JAK1/JAK2 inhibitor with lower inhibitory potency toward TYK2, which is in clinical use for the treatment of patients with rheumatoid arthritis or atopic dermatitis and is under investigation for a large number of inflammatory and autoimmune diseases [28–30]. Published data from a double-blind, randomized, placebo-controlled trial in 1033 hospitalized COVID-19 patients demonstrated that baricitinib in combination with remdesivir resulted in reduced hospitalization period and accelerated recovery time in critically ill patients receiving high-flow oxygen or noninvasive ventilation compared to remdesivir alone [31]. Thus, inhibition of multiple cytokines' signaling seems to be more promising than manipulating the action of single cytokines. In November 2020, baricitinib received an emergency use authorization by the FDA for the treatment of severely ill COVID19 patients. While the immunological effects achieved with baricitinib may also be valid for some other JAK inhibitors, some off-target effects seem to be unique for baricitinib. As suggested by bioinformatic approaches and confirmed by in vitro models and kinase assays, baricitinib could reduce cellular infection by blockade of numb-associated kinase members that are implicated in receptor-mediated viral endocytosis [32, 33]. Baricitinib shows nanomolar affinity for the numb-associated kinase family members' AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK) and reduces the viral load in liver spheroids infected with SARS-CoV-2 [33]. Like other clinically advance staged JAK inhibitors, baricitinib potently suppresses the intracellular signaling of cytokines such as IL-6, IFN-α, or IFN-γ in vitro [34] and in a rhesus macaque model of SARS-CoV-2 infection, where JAK1/JAK2 blockade also showed a significant decrease in macrophages and neutrophils infiltrating the lungs [35].

Baricitinib along with other JAK inhibitors may be a better strategy than dexamethasone. The use of baricitinib in COVID-19 patients was not associated with an increase in thromboembolic events and infection-related adverse events were fewer than in the placebo group [31]. This was not expected, since virus reactivation (i.e., herpes zoster) is normally observed in patients under JAK inhibitor treatment. Of note, no increase in thromboembolic events was observed, although such events are frequent in SARS-CoV-2-infected patients and appear in patients receiving JAK inhibitors for autoimmune diseases [36]. While clinical trials with baricitinib for COVID-19 patients are ongoing, the efficacy and safety of other JAK inhibitors alone or in combination with other agents are under clinical investigation in the setting of SARS-CoV-2-infected patients (Table 1). Most of these inhibitors tested are either selective for JAK1/JAK2 (baricitinib, ruxolitinib) or JAK1/JAK3 (tofacitinib), given orally and approved for other diseases than COVID-19. Interestingly, one pan-JAK inhibitor (TD-0903), originally developed as topical JAK inhibitor for preventing graft rejection in patients with
Conflict of interest: The authors declare no commercial or financial conflict of interest.

Acknowledgement: The work was supported by the Deutsche Forschungsgemeinschaft (DFG) FOR 2497/TP02 (GH133/2-2) to Kamran Ghoreschi. Open access funding enabled and organized by Projekt DEAL.

Table 1. Current trials with Janus kinase inhibitors in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients

| JAK inhibitor | Target | COVID-19 patient population | Administration | Trial phase | NCT number |
|---------------|--------|-----------------------------|----------------|------------|------------|
| Ruxolitinib   | JAK1/2 | ARDS                        | Oral           | 2/3        | NCT04477993|
| Ruxolitinib   | JAK1/2 | ARDS with ventilation       | Oral           | 3          | NCT04377620|
| Baricitinib   | JAK1/2 | Moderate to Severe          | Oral           | 2          | NCT04321993|
| Tofacitinib$^{a,1}$ | JAK1/3 | Interstitial pneumonitis    | Oral           | 2          | NCT04390061|
| TD-0903       | Pan-JAK| Symptomatic acute lung injury| Inhalation     | 2          | NCT04402866|
| Ruxolitinib   | JAK1/2 | Pneumonia                   | Oral           | 2          | NCT04334044|
| Ruxolitinib$^{b,2}$ | JAK1/2 | Severe stages 2b/3         | Oral           | 3          | NCT04424056|
| Ruxolitinib   | JAK1/2 | Pneumonia                   | Oral           | NA         | NCT04331665|
| Tofacitinib   | JAK1/3 | Pneumonia                   | Oral           | 2          | NCT04322042|
| Baricitinib$^{c}$ | JAK1/2 | Mild to moderate            | Oral           | 2/3        | NCT04320277|
| Ruxolitinib   | JAK1/2 | Safety & Efficacy           | Oral           | 2/3        | NCT04348071|
| Baricitinib   | JAK1/2 | Safety & Efficacy           | Oral           | 2/3        | NCT04340232|
| Ruxolitinib   | JAK1/2 | Pneumonia                   | Oral           | 2          | NCT04399798|
| Ruxolitinib$^{3}$ | JAK1/2 | Pneumonia                   | Oral           | 1/2        | NCT04581954|
| Baricitinib$^{d,4}$ | JAK1/2 | Hospitalized Patients       | Oral           | 3          | NCT04640168|
| Ruxolitinib   | JAK1/2 | ARDS                        | Oral           | 2          | NCT04359290|
| Ruxolitinib$^{b,5}$ | JAK1/2 | Pneumonia                   | Oral           | 2          | NCT04366232|

In combination with hydroxychloroquine$^6$, anakinra or tocilizumab$^9$, ritonavir$^c$, and remdesivir$^d$. Compared to treatment group with hydroxychloroquine alone$^1$, standard of care, anakinra and tocilizumab alone$^2$, to standard of care and fosfatinib$^3$, to dexamethasone with baricitinib$^4$, to anakinra alone$^5$.

References

1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L. et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. 395: 497–506.
2. Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D. et al., Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2020. 384: 403–416.
3. Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L. et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020. 383: 2603–2615.
4. Schijns, V. and Lavelle, E. C., Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Eur. J. Immunol. 2020. 50: 922–938.
5. Galani, I. E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E. et al., Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021. 22: 32–40.
6. Oja, A. E., Saris, A., Ghandour, C. A., Kragten, N. A. M., Hogema, B. M., Nossent, E. J., Heunks, L. M. A. et al., Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. Eur. J. Immunol. 2020. 50: 1998–2012.
7. Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A. et al., Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur. J. Immunol. 2020. 50: 2013–2024.
8. Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Moller, R., Jordan, T. X. et al., Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020. 181: 1036–1045, e1039.
9. Merad, M. and Martin, J. C., Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 2020. 20: 355–362.
Della-Torre, E., Landoni, G., Zangrillo, A. and Dagna, L., Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘correspondence on: ‘interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang. Ann. Rheum. Dis. 2020. http://doi.org/10.1136/annrheumdis-2020-218724

Investigators, R.-C., Duncan, C. J., Hamming, I., Ziegler, C. G. K., in patients with psoriasis-insights from a global registry-based study. Eur. J. Immunol. 2021. 51: 1071–1075

Rosas, I. O., Brau, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D. et al., Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 2021. https://doi.org/10.1056/NEJMoa2028700

Gisondi, P., Piaseiro, S., Naldi, L., Dapavo, P., Conti, A., Malagoli, P., Marzano, A. V. et al., Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J. Allergy Clin. Immunol. 2021. 147: 558–560.

Mahil, S. K., Dand, N., Mason, K. J., Yu, Z. N. Z., Tsakok, T., Meynell, F., Coker, B. et al., Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J. Allergy Clin. Immunol. 2021. 147: 60–71.

Hadjij, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H. et al., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020. 369: 718–724.

Mommert, M., Perret, M., Hockin, M., Viel, S., Belot, A., Richard, J. C., Mezidi, M. et al., Type-I interferon assessment in 45 minutes using the FilmArray(R) PCR platform in SARS-CoV-2 and other viral infections. Eur. J. Immunol. 2021. 51: 989–994.

Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y., Dorgam, K. et al., Autoantibodies against type 1 IFNs in patients with life-threatening COVID-19. Science 2020. 370. https://doi.org/10.1126/science.abb4585

Oldstone, M. B., Teijaro, J. R., Walsh, K. B. and Rosen, H., Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. Virology 2013. 435: 92–101.

Ziegler, C. G. K., Allen, S. J., Nyquist, S. K., Miano, I. M., Miao, V. N., Tsouzas, C. N., Cao, Y. et al., SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020. 181: 1016–1035 e1019.

Hamming, I., Timens, W., Bulthuis, M. L., Lely, A. T., Navis, G. and van Goor, H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004. 203: 631–637.

Hernandez, N., Bucciol, G., Moens, L., Le Pen, J., Shahrooei, M., Goudouris, E., Shirkani, A. et al., Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J. Exp. Med. 2019. 216: 2057–2070.

Duncan, C. J., Mohamad, S. M., Young, D. F., Skelton, A. J., Leahy, T. R., Munday, D. C., Butler, K. M. et al., Human IFNAR2 deficiency: lessons for antiviral immunity. Sci. Transl. Med. 2015. 7: 307ra154.

Kreins, A. Y., Ciancanelli, M. J., Okada, S., Kong, X. F., Ramirez-Alejo, N., Kilic, S. S., El Baghdadi, J. et al., Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 2015. 212: 1641–1662.

Pairol-Castineira, E., Clohisey, S., Klaric, L., Bretherton, A. D., Rawlik, K., Pasko, D., Walker, S. et al., Genetic mechanisms of critical illness in Covid-19. Nature 2021. 591: 92–98.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J. and Hih Across Speciality Collaboration, U. K., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020. 395: 1033–1034.

Boudevijs, R., Thibaut, H. J., Kaptein, S. J. F., Li, R., Vergote, G., Seldeslachts, L., Van Weyenbergh, J. et al., STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 2020. 11: 5838.

Vannucchi, A. M., Sordi, A., Moretini, A., Nozzoli, C., Poggesi, I., Pieralli, F., Bartoloni, A. et al., Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia 2020. https://doi.org/10.1038/s41375-020-01018-y

Welsch, K., Holstein, J., Laurence, A. and Ghoreschi, K., Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur. J. Immunol. 2017. 47: 1096–1107.

Solimani, F., Meier, K. and Ghoreschi, K., Emerging topical and systemic JAK inhibitors in dermatology. Front. Immunol. 2019. 10: 2847.

Ghoreschi, K., Balato, A., Enerback, C. and Sabat, R., Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021. 397: 754–766.

Kail, A. C., Patterson, T. F., Mehta, A. K., Tomaszek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 2020. 384: 795–807.

Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M. et al., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020. 395: e30–e31.

Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V. et al., Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol. Med. 2020. 12: e12697.

Kubo, S., Nakayamada, S., Sakata, K., Kitanaga, Y., Ma, X., Lee, S., Ishii, A. et al., Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front. Immunol. 2018. 9: 1510.

Hoang, T. N., Pino, M., Boddapati, A. K., Viox, E. G., Starke, C. E., Upadhyay, A. A., Gumber, S. et al., Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 2020. https://doi.org/10.1016/j.cell.2020.09.16.300277

Bilaloglu, S., Abyanaphongs, V., Jones, S., Iturrate, E., Hochman, J. and Berger, J. S., Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. JAMA 2020. 324: 799–801.

Ghoreschi, K., Laurence, A. and O’Shea, J. J., Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 2009. 10: 356–360.

Abbreviation: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

Full correspondence: Dr. Kamran Ghoreschi, Department of Dermatology, Venerology and Allergology, Charité–University Medicine Berlin, Charitéplatz 1, Berlin 10117, Germany Email: kamran.ghoreschi@charite.de

Received: 8/1/2021
Revised: 8/1/2021
Accepted: 1/3/2021
Accepted article online: 5/3/2021